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Production of type I interferons: plasmacytoid dendritic 
cells and beyond
 
Carine Asselin-Paturel and Giorgio Trinchieri
 
Plasmacytoid dendritic cells (pDCs) are specialized producers of type I 
interferons (IFNs) that respond to most viruses. Because of their antiviral 
activity and regulatory functions in innate and adaptive immunity, type I IFNs 
are important not only for antiviral resistance but also in other types of 
infections and in immune pathology. Here we discuss recent data that begin to 
reveal the unique molecular mechanisms underlying the remarkably rapid and 
efficient type I IFN production by pDCs.
 
Plasmacytoid DCs in mice and men
 
The first evidence for the existence of a
cell type specialized for the production
of type I IFNs (IFN-
 
 
 
, IFN-
 
 
 
) came
from human studies showing that a
non-T, non-B, nonmonocytic cell type
was required for NK cell–mediated kill-
ing of virus-infected cells or tumor cell
lines. These cells mediated activation of
NK cells through secretion of type I
IFNs (1) and were defined as natural
interferon-producing cells (NIPCs).
NIPCs  were characterized by several
groups in the 1980s and found to be a
rare HLA class II–positive cell type dis-
tinct from conventional dendritic cells
(cDCs) (2). NIPCs were recently found
to correspond to plasmacytoid cells that
had previously been identified in the T
cell zone of human lymphoid tissue
and in peripheral blood, now known as
pDCs (2, 3).
pDCs have a round morphology
with an eccentric nucleus and abundant
endoplasmic reticulum (thus “plasma-
cytoid”). When activated in vitro with
interleukin (IL)-3 and CD40 ligand
(CD40L) they acquire a dendritic cell
morphology and many DC functions
(Fig. 1) (2). Importantly, pDCs express a
different profile of the microbial pattern
recognition Toll-like receptors (TLRs)
than cDCs (4). cDCs preferentially ex-
press TLR3, TLR8, and low levels of
TLR2 and TLR4, whereas pDCs prefer-
entially express TLR7 and TLR9. TLR7
and TLR9 are intracellular endosomal
receptors that allow pDCs to respond to
single stranded RNA and DNA viruses,
respectively, by triggering signal trans-
duction through the adaptor protein
MyD88.
Early in vitro studies in humans
showed that pDCs are the only cell type
within peripheral blood that efficiently
produces type I IFNs in response to cer-
tain viruses, including inactivated ones.
Thus, they were also hypothesized to
produce most type I IFN during in vivo
virus infection. However, it is well
known that most cells, including cDCs
(5, 6) and other cells, hematopoietic or
not, produce type I IFN when exposed
to viruses. One key difference between
pDCs and other cell types is that TLR7
or TLR9 ligation induces efficient pro-
duction of type I IFNs in pDCs (Fig. 2),
but not in other cells expressing these
receptors (such as B lymphocytes). Type
I IFNs are produced by other cell types
in response to triggering of TLR3 and
TLR4 by their ligands double stranded
RNA (dsRNA) and lipopolysaccharide,
respectively. TLR3 and TLR4 signal
through the adaptor molecule TRIF that
associates with the kinase TBK1 and
induces phosphorylation and nuclear
translocation of the transcription factor
interferon regulatory factor (IRF)-3.
Type I IFNs are also induced by ac-
tivation of cytoplasmic receptors, in-
cluding those that recognize dsRNA.
Although the dsRNA-binding protein
kinase R (PKR) was initially described to
play an important role in type I IFN
production (6), gene silencing studies
have indicated that the RNA helicases
encoded by retinoic 
 
acid-inducible gene I
 
(
 
RIG-I
 
) and, likely, 
 
melanoma differentia-
tion-associated gene 5
 
 (
 
MDA-5
 
) are the
prevalent cytoplasmic receptors responsi-
ble for triggering type I IFN secretion
(7). TLR3 and TLR4, which are ex-
pressed in cDCs and other cells types,
are minimally expressed by pDCs,
whereas the cytoplasmic dsRNA recep-
tors are expressed by most cells. The
production of type I IFNs is further
regulated by a positive feedback loop
that is based on the ability of IFN-
 
 
 
 (in
mice and humans) and IFN-
 
 
 
4 (in
mice)—produced in response to acti-
vated IRF-3 and other transcriptional
factors—to induce the transcription of
other signaling proteins, such as IRF-7
(8) and likely IRF-8 (Tailor, P., and K.
Ozato, personal communication). Once
phosphorylated, these transcription fac-
tors help drive the expression of all the
genes of the type I IFN family, thereby
amplifying type I IFN production. Thus,
the unique pattern of TLR expression
and the molecular mechanisms respon-
sible for type I IFN production do not
alone explain the exquisite ability of
pDCs to produce type I IFNs.
NIPCs and pDCs were not identi-
fied in mice until 2001, years after their
human counterparts (2). The character-
ization of mouse pDCs finally allowed
the investigators to test whether these
cells play a predominant role in type I
IFN production during virus infection.
Upon infection of mice with many
DNA viruses, such as murine cytomeg-
alovirus (MCMV) or vesicular stomatitis
virus (VSV), pDCs were shown to be
responsible for the majority of the type I
IFN production in vivo, confirming the
specialized role of these cells (2, 9–11).
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However, this was not the case with
other viruses, such as lymphocytic
choriomeningitis virus (LCMV) and
West Nile virus (2, 10). Although the
peak of type I IFN production at 48 h
after LCMV infection was not de-
creased by depleting the mice of pDCs
(10), these cells were shown to produce
some type I IFN at earlier times after
infection (12). Similarly, although the
peak production of type I IFNs at 36 h
after MCMV infection was MyD88
dependent and was almost completely
abolished if pDCs were depleted, a
minor peak of type I IFN production
occurred a few hours later and was
MyD88, pDC, and, most likely, TLR
independent (13). cDCs contributed to
the second peak of type I IFN produc-
tion and were fully capable of activat-
ing the antiviral activity of NK cells in
the spleen of MCMV-infected animals,
indicating that pDCs are not essential
for this function in vivo (13). How-
ever, the exact identification of the cell
type(s) other than pDCs that are re-
sponsible for producing type I IFNs in
vivo has proven difficult, and many dif-
ferent cell types are likely to be in-
volved, including cDCs and macro-
phages as well as nonhematopoietic cells.
 
Type I IFNs in DC maturation 
and function
 
Mice lacking functional type I IFN re-
ceptors (
 
IFNAR
 
 
 
/
 
 
 
) have provided a
useful model for analyzing the role of
type I IFNs in DC maturation and
function. cDCs are only partially de-
pendent on type I IFNs for their mat-
uration (5) and do not require these
cytokines for activation-induced mi-
gration to the central T cell zones in
the spleen (14). Unlike cDCs, the mat-
uration of pDCs in response to TLR7
or TLR9 agonists is drastically reduced
in the absence of type I IFN signaling,
as is their migration to and clustering in
the marginal zone of the spleen (14),
suggesting an important role for posi-
tive feedback in plasmacytoid pDC mi-
gration and function in vivo.
Type I IFNs produced during virus
infection inhibit the production of the
Th1-promoting cytokine IL-12 by
cDCs. IL-12 production is recovered if
pDCs are depleted or type I IFN sig-
naling is prevented (10). However, the
effect of type I IFNs on IL-12 produc-
tion is somewhat paradoxical: high lev-
els of type I IFNs, such as those pro-
duced during virus infection, inhibit
IL-12 production mostly by decreasing
transcription of the IL-12p40 chain,
whereas lower levels of type I IFNs are
actually required for the efficient tran-
scription of the 
 
IL-12p35
 
 
 
gene
 
 and thus
for the production of the biologically
active IL-12 heterodimer (IL-12 p70)
(15). The type I IFN required for IL-
12 p70 production is produced in an
autocrine manner by cDCs rather than
by pDCs. This cDC-derived type I
IFN is partly responsible for the syn-
ergy of IL-12 p70 production that is
observed when TRIF-dependent and
MyD88-dependent TLRs are triggered
simultaneously (15).
 
Mechanisms of type I IFN production 
by pDCs
 
Mouse studies confirmed that pDCs
were potent producers of type I IFNs in
vivo
 
,
 
 but the unique molecular mecha-
nisms that endowed them with this
ability remained to be determined.
IRF-3, which is required for type I IFN
production in response to TLR3 and
TLR4, is neither required for nor acti-
vated by TLR7/9 signaling in pDCs
(16). Instead, IRF-7 is required for type
I IFN production in response to
TLR7/9 (16). Ligation of TLR7 or
TLR9 in pDCs activates a signaling
complex composed of MyD88, IRAK-1,
and TRAF6, which physically associ-
ates with IRF-7 and is required for the
production of type I IFNs (17, 18). Un-
like IRF-7, IRF-5, which also forms a
complex with MyD88 and TRAF6
downstream of TLR7/9, is required for
the transcription of proinflammatory
genes such as 
 
IL-6
 
, 
 
TNF
 
, and 
 
IL-12
p40
 
 (16, 19). Contrasting results have
been reported regarding whether IRF-5
can substitute for IRF-7 to stimulate
type I IFN induction (16, 19).
Both human and mouse pDCs con-
stitutively express somewhat higher
levels of IRF-7 than other cell types
and this could account for the ability of
pDCs to produce type I IFNs in the
absence of positive feedback driven by
de novo IRF-7 induction (20, 21).
pDCs also constitutively express IRF-8
that, similarly to IRF-7, appears to be
involved in positive feedback (22). In-
deed, type I IFN production by pDCs
is in part independent of this positive
Figure 1. Human plasmacytoid DCs. Optical microscopy (A), transmission electron microscopy (B), and 
scanning electron microscopy (C) images showing the typical morphology of human pDCs. (D) Scanning 
electron microscopy image showing the dramatic morphological changes of activated pDCs after culture 
in the presence of IL-3 and CD40 ligand. All images are reproduced from Grouard et al. (3).
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feedback. In 
 
IFNAR
 
 
 
/
 
 
 
 mice type I
IFN production is reduced but not ab-
sent in response to MCMV and VSV
infection or to the TLR7 ligand R848
(10, 14). However, 
 
IFNAR
 
 
 
/
 
 
 
 pDCs
produce only minimal levels of type I
IFNs in vivo in response to the TLR9
ligand CpG oligodeoxynucleotides
(ODNs), indicating that in some con-
ditions pDCs require positive feedback
for type I IFN production (14).
The constitutive expression of
IRF-7 is not sufficient to explain why
only pDCs, and not other TLR7- or
TLR9-expressing cells, efficiently pro-
duce type I IFNs. Indeed, IRF-7 is
rapidly induced, through both type I
IFN-dependent and -independent
mechanisms, in all cells at the site of vi-
rus infection. In fact, the level of IRF-7
induction in these cells is much
higher than those constitutively present
in the pDCs, yet the participation of
other cells in type I IFN production in
response to viruses or other TLR7 and
TLR9 ligands is minimal.
In a recent study, a mechanism that
likely accounts for the preferential abil-
ity of pDCs to produce type I IFNs
was described. The study showed that
the intracellular translocation of CpG
ODNs bound to TLR9, as well as the
ability of TLR9 to induce IRF-7 acti-
vation, are differentially regulated in
pDCs and in other TLR9-expressing
cell types (23). In pDCs, the TLR9-
associated MyD88–IRF-7 complex was
retained in the endosomal compart-
ment for over 90 min after treatment
with CpG ODNs. In other cell types,
the complex rapidly translocated to ly-
sosomes. This was observed only with
type A CpG ODNs, which are effi-
cient inducers of type I IFN produc-
tion. However, when type A CpG
ODNs were formulated within cat-
ionic liposomes (DOTAP), they caused
the TLR9–MyD88–IRF-7 complex to
be retained in the endosomal compart-
ment and induced type I IFN produc-
tion in cDCs and other cells that nor-
mally do not produce these cytokines.
Type B CpG ODNs, which preferen-
tially induce proinflammatory cyto-
kines other than type I IFNs, induced
rapid translocation of the MyD88–
IRF-7 complex to lysosomes in both
pDCs and cDCs. However, type B
CpG ODNs formulated in DOTAP
retained the TLR9 signaling complex
in the endosomal compartment and in-
duced type I IFN secretion in pDCs.
The results above on the effect of
formulation of CpG ODNs in lipo-
somes are compatible with data indicat-
ing that type A CpG ODNs, unlike
type B CpG ODNs, have the ability to
spontaneously form multimolecular
complexes assembled in nanoparticles
(24). Type B CpG ODNs loaded on
polysterene nanoparticles acquired the
ability to induce type I IFNs (24).
Thus, type I IFN production in re-
sponse to TLR9 ligation requires a spa-
tiotemporal regulation of the MyD88–
IRF-7 complex such that it is retained
in the endosomal compartment. This is
observed only in pDCs unless the CpG
ODNs are formulated in cationic lipo-
somes or nanoparticles and are thus
trapped in the endosomes. This pro-
vides an explanation for the unique
ability of these cells to produce type I
IFN in response to TLR9 and probably
TLR7 ligands (23). The complex of
nucleic acids and cationic liposomes
may mimic TLR9-activating viruses
that accumulate in endosomes (23).
TLR9 and probably TLR7 bind their
ligands at low pH (5.0–6.5); thus, the
interaction between receptor and li-
gand could take place in early endo-
somes (pH 6.3–6.5), in the endosomal
carrier vesicles (pH 5.0–5.5), or in the
late endosomes/lysosomes (pH 
 
 
 
5.0).
In nonstimulated cells, TLR9 is local-
ized in the endoplasmic reticulum
(ER) (25), but after the cells are ex-
posed to CpG ODNs it associates ei-
ther with endosomes or with lyso-
somes, depending on the type and
formulation of CpG ODNs and the re-
Figure 2. Major signaling pathways for type I IFN gene transcription. TLR7 and TLR9 are highly 
expressed on pDCs and, depending on the chemical properties and formulation of the ligands used 
and on the cell type, activate signaling pathways involving either IRF-7 or IRF-5 and NF- B. The IRF-7 
pathway preferentially induces transcription of the type I IFN gene family and it is activated when the 
TLR–MyD88–IRAK–IRF-7 complex is retained in the endosomal compartment, as observed in pDCs 
treated with type A CpG ODNs. Other receptors able to induce production of type I IFN are TLR3 and 
TLR4 signaling through the adaptor molecule TRIF and the kinase TBK-1. TLR4, in addition to TRIF, also 
utilizes the adaptors TRAM, MyD88, and TIRAP (not shown in the figure). The cytoplasmic dsRNA re-
ceptor RIG-I also utilizes TBK-1. IRF-7 is required for optimal production of type I IFN induced by all 
these receptors, whereas IRF-3 is essential only for the response to TLR3 or TLR4. A positive feedback 
mechanism for IFN production involves the de novo synthesis of IRF-7 and IRF-8 in response to type I 
IFNs that amplify the transcription of all the genes of the type I IFN family.
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sponding cell type. The lack of fully
glycosylated forms of TLR9 in CpG-
stimulated cells suggests that the ER
might directly communicate with the
endosomal compartment under these
conditions, although a more canonical
pathway through the Golgi and into
endosomal carrier vesicles cannot be
completely excluded (25). The mecha-
nisms that determine the delayed
movement from endosomes to lyso-
somes in CpG-stimulated pDCs or in
other cells exposed to CpG ODNs for-
mulated in cationic liposomes remain
unknown. It is also unclear why activa-
tion of the TLR9–IRF-7 signaling
pathway takes place in endosomes,
whereas the TLR9–NF-
 
 
 
B–IRF-5
pathway is activated in lysosomes. It is
possible that retention in the endoso-
mal compartment allows the receptor
to interact with its ligand for a longer
period of time and that this prolonged
interaction may be required for IRF-7
activation but not for IRF-5 and NF-
 
 
 
B activation. Alternatively, prolonged
signaling through TLR9 may phos-
phorylate de novo–produced IRF-7,
thus allowing the activation of the pos-
itive feedback and optimal production
of type I IFNs (26).
 
Why do we need a specialized type I 
IFN-producing cell?
 
Although type I IFNs are mostly pro-
duced by pDCs during several virus in-
fections, depending on the virus, a
variable proportion of type I IFN is
also produced by other cell types, in-
cluding cDCs (5, 6, 13). Type I IFNs
produced by cell types other than
pDCs have important direct antiviral
effects and immunomodulatory effects
such as the activation of NK cells and
the efficient and early production of
the IL-12 p70 heterodimer (13, 15).
Yet, one may speculate why it is useful
for the organism to have a specialized
IFN-producing cell type. Not only are
pDCs wired for a rapid production of
high levels of type I IFNs, but the
TLR7 and TLR9 used by these cells—
unlike other receptors leading to type I
IFN production—respond to viral nu-
cleic acid from inactivated or noninfec-
tious viruses and do not require infec-
tion of the cells. This is beneficial, as
many viruses have developed mecha-
nisms to block the production of type I
IFNs early after infection (27). In gen-
eral the viral strategies used to block
type I IFN production are not effective
in pDCs because either the cells are not
infected or the virus targets signaling
pathways for type I IFN induction
other than those used by TLR7 and
TLR9 (6). Exceptions are measles virus
and respiratory syncytial virus, which
specifically inhibit type I IFN produc-
tion in pDCs (27), and human herpes
virus 8, which specifically blocks IRF-7
with its ORF45 protein (28).
Despite the importance of type I
IFN production in vivo, it should be
noted that a unique and essential func-
tion for the type I IFNs that are pro-
duced by pDCs has not yet been identi-
fied and that much work remains to be
done to understand the precise biologic
role of pDCs both as type I IFN pro-
ducers and as accessory cells in innate
resistance and adaptive immunity (2).
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